{"id":"W2969712092","doi":"10.1016/j.eururo.2019.07.048","title":"First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; University of Calgary","funders":"National Cancer Institute; Foundation Medicine; Pfizer Japan; Novartis Pharma; EMD Serono; Genentech; Ipsen; Alexion Pharmaceuticals; Eisai; National Comprehensive Cancer Network; Sanofi; Exelixis; GlaxoSmithKline; Astellas Pharma; Celldex Therapeutics; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Metastasis; Carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001733163,0.00053176,0.0008455242,0.0003597005,0.0001251739,0.00005021171,0.0007186348,0.0000857349,0.0006929453],"category_scores_gemma":[0.00037331,0.000387735,0.0002339586,0.0003323891,0.0002925603,0.0001723119,0.0004245429,0.0007314819,0.001125038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000352249,"about_ca_system_score_gemma":0.0002683061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001103037,"about_ca_topic_score_gemma":0.0003859098,"domain_scores_codex":[0.9945741,0.001895336,0.001302163,0.00104263,0.0005507706,0.0006350203],"domain_scores_gemma":[0.9953083,0.002180791,0.0006679985,0.001429265,0.0002372785,0.0001764015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.04442232,0.016746,0.2973049,0.0006173155,0.002975732,0.0378916,0.03154795,0.004737852,0.5061282,0.001770992,0.04777095,0.008086187],"study_design_scores_gemma":[0.08193529,0.01134901,0.7313468,0.0001110068,0.002187482,0.001029039,0.00186258,0.007039044,0.03587783,0.0005740468,0.1254354,0.001252459],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9606985,0.003294744,0.0001481593,0.008544776,0.0008177896,0.001348295,0.0003738864,0.00006557791,0.02470824],"genre_scores_gemma":[0.9909528,0.0001987306,0.00109602,0.00247389,0.0001835948,0.00005234197,0.002327894,0.0001097159,0.002605023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4702504,"threshold_uncertainty_score":0.9998574,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03263677506092706,"score_gpt":0.2628622018563442,"score_spread":0.2302254267954172,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}